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Crohn’s disease (CD) is an inflammatory disorder of the gastrointestinal tract that is likely caused by an inappropriate mucosal
inflammatory response to intestinal bacteria in a genetically predisposed host. The lesions of CD can involve any region of the GI
tract as well as extraintestinal sites such as the skin, joints, and eyes. The most common presenting symptoms are abdominal pain
and prolonged diarrhea associated with fevers, fatigue, and malaise. Delayed growth and failure to thrive may also be observed in
pediatric patients. Oral manifestations of CD are known as oral CD and may precede GI involvement, thus serving as early markers
of this condition. We describe a 6-year-old male who presented with oral lesions as his initial manifestation of disease and review
the current literature pertaining to oral CD.

1. Introduction
Crohn’s disease (CD) is an immune-mediated disorder of the
gastrointestinal (GI) tract which, along with ulcerative colitis,
comprises the two major subsets of the inflammatory bowel
disease (IBD). The underlying etiology is poorly understood
but likely involves defects in mucosal immunity and intestinal
epithelial barrier function in a genetically susceptible individual, leading to an inappropriate inflammatory response to
intestinal microbes [1–3]. The lesions of CD can involve any
portion of the alimentary tract from the mouth to anus [4, 5].
Extraintestinal sites such as the skin, joints, and eyes may be
affected as well. The most common presenting symptoms are
periumbilical abdominal pain and diarrhea associated with
recalcitrant fevers, malaise, fatigue, and anorexia [1, 4, 5]. Oral
involvement is identified in up to 80% of patients [4, 6, 7]
and may precede GI involvement in some cases. We describe
a pediatric patient whose initial presentation of CD was
multifocal gingival erythema and swelling.

2. Case Report
A 6-year-old male presented with his mother for evaluation of
painful and bleeding gingiva. The patient’s mother reported
that the gingival changes began seven months ago and that

the onset was not associated with any identifiable inciting
events, including mechanical, thermal, and chemical trauma;
dietary changes; use of new dental hygiene products; or
exposure to cinnamon-containing products or foodstuffs. She
also denied a history of fever, malaise, and GI symptoms.
The patient had seen his pediatrician two weeks prior and
undergone a complete blood count (CBC) and metabolic
panel, which revealed no abnormalities. A thorough dental
prophylaxis had also been performed one week prior with no
significant improvement in the appearance of his gingiva.
The patient’s medical history was significant for asthma,
for which he was using mometasone furoate inhaler once
daily and albuterol sulfate inhaler on an as-needed basis. His
mother stated that he took special care rinsing his mouth
after use of the steroid inhaler as directed by his pediatrician. His review of systems and family history were otherwise unremarkable for cardiovascular, endocrinologic, GI,
genitourinary, musculoskeletal, hematologic, and neurologic
disorders.
Intraoral examination revealed a very subtle area of
mucosal erythema involving the gingiva buccal to the right
primary maxillary molar, canine, and lateral incisor (Figure 1)
and a more well-defined area of erythema involving the
alveolar mucosa facial to the left primary maxillary central
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Figure 1: Mild mucosal erythema of the right anterior maxillary
gingiva.

Figure 2: A demarcated area of mucosal erythema involving the left
anterior maxillary alveolar mucosa.

and lateral incisors and canine (Figure 2). Also noted were
multiple mucosal-colored swellings and ulcerations of the
gingiva facial to the right permanent mandibular central and
lateral incisors and primary canine (Figure 3). Mild tenderness was elicited on gentle palpation of the affected sites.
The remainder of the oral mucosal examination was within
normal limits. No bone loss was evident on radiographic
examination.
As requested by the referring periodontist, biopsy of
the affected mandibular gingiva was performed. Microscopic
examination revealed curved portions of oral mucosa surfaced by spongiotic stratified squamous epithelium with
evidence of mild inflammatory cell exocytosis; beneath the
epithelium, there was a proliferation of fibrous connective
tissue with a patchy infiltrate of lymphocytes and plasma cells
(Figure 4(a)). In isolated areas, there were well-formed, noncaseating granulomas composed of epithelioid histiocytes
and lymphocytes (Figure 4(b)). Periodic Acid-Schiff (PAS),
Grocott-Gomori’s methenamine silver (GMS), and Acid-Fast
Bacilli (AFB) stains were performed to rule out deep fungal
infections and mycobacterial infections such as tuberculosis
and leprosy as causes of the granulomas. All stains were
negative. Examination of the biopsy under both light and
polarized light microscopy did not reveal foreign body
material. Hence, a diagnosis of granulomatous inflammation
was rendered with a comment pertaining to possible etiologies such as Crohn’s disease, orofacial granulomatosis, and
sarcoidosis.

Case Reports in Dentistry

Figure 3: Nodular swellings of the interdental papillae between the
right permanent mandibular central and lateral incisors and primary canine. An ulceration of the free gingival margin between the
incisors is seen. Also noted is a linear ulceration with hyperplastic
margins involving the alveolar mucosa.

The patient was provided with a prescription for a mild
topical steroid rinse and instructed to rinse and spit four
times daily for 14 days. He was also referred to his pediatrician
for additional evaluation to rule out for Crohn’s disease and
other systemic conditions associated with granulomatous
inflammation, including sarcoidosis. The patient returned
for follow-up three weeks later and demonstrated a modest
reduction in the erythema of the maxillary gingiva and
swelling of the mandibular gingiva. The patient’s mother
also reported less pain and bleeding during brushing. The
patient was again advised to pursue diagnostic evaluation
for systemic causes of granulomatous inflammation. Following evaluation by his pediatrician, he was referred to
a pediatric gastroenterologist for consultation. The patient
subsequently underwent endoscopic examination and biopsy
which showed acute inflammation of the intestinal mucosa.
A diagnosis of early Crohn’s disease was made. The patient
was placed on mesalamine, an anti-inflammatory aminosalicylate, and azathioprine, an immunosuppressant. At oneyear follow-up by phone, the patient’s mother reports that
he continues to respond well to his medications. She states
that his oral lesions have completely resolved and that he is
currently free of intraoral and GI symptoms.

3. Discussion
CD is a multisystem, inflammatory disorder with a complex
etiologic basis that is believed to involve an interplay of
genetic, immunologic, and environmental factors [1]. It has
been postulated that changes in the immune system and
exposure to environmental risk factors are necessary triggers
of disease [1]. The increasingly accepted theory is that CD is
the result of an inappropriate mucosal inflammatory response
to intestinal bacteria in a genetically predisposed host [2,
3]. Although a specific organism has yet to be consistently
identified in CD patients [8, 9], the presence of bacteria
appears to be an obligatory event in the pathogenesis of
this disorder. This is supported by in vivo murine models
of CD, in which the induction of mucosal inflammation is
dependent on microbial stimulation [4]. As a corollary, it
has also been shown that inflammation does not occur in
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(a)

(b)

Figure 4: Histopathologic images of the right mandibular gingiva. (a) Low-power view showing stratified squamous epithelium with scattered
intraepithelial lymphocytes (exocytosis). The underlying fibrous connective tissues are characterized by a patchy chronic inflammatory cell
infiltrate and an isolated granuloma (arrow) (hematoxylin and eosin, 40x). (b) High-power view showing a well-defined, noncaseating
granuloma composed predominantly of epithelioid histiocytes and lymphocytes (hematoxylin and eosin, 100x).

mice raised in a bacteria-free environment [1, 4]. Although
similar observations have been reported in human studies,
the causative role of bacteria in these investigations remains
speculative. It is noteworthy that the microbiota in the intestine is complex and consists of organisms that can potentially exert pro- and anti-inflammatory effects [4]. The shift
towards an inflammatory state in CD is believed to be caused
by alterations in the intestinal flora and the host’s mucosal
response, which is influenced by both genetics and immunity
[4].
The role of genetics in the pathogenesis of CD was suggested early on with recognition of familial clustering and
twin concordance among affected patients [4, 9–12]. A positive family history remains the most important independent
risk factor for developing CD to date [4, 13]. More recently,
genome-wide analysis studies have revealed more than 30
loci associated with CD [1, 14, 15]. Of significance may be
the genetic polymorphisms that alter adaptive immunity
and the mutations associated with inadequate surveillance
of bacteria by the intestinal mucosa [16–20]. The cumulative
effect of these genetic aberrations may be the development
of abnormal immune tolerance to intestinal antigens [21,
22]. The inappropriate mucosal inflammatory response that
ensues is likely a result of immune system dysregulation.
Immunologic mechanisms proposed to be involved in CD
include impairment of the innate immune system, leading to
a sustained proinflammatory environment in the intestines
[1]; excessive activation and differentiation of T-cell subsets
against mucosal antigens [23–25]; and aberrant cytokine
secretion [26, 27]. In particular, the cytokine IFN-𝛾 appears
to play a key role in maintaining the inflammatory milieu
in the intestine [4]. Such findings may be significant in the
development of more targeted CD therapies [4].
Lastly, certain environmental factors have been implicated in the pathogenesis of CD. These include sociodemographic factors such as economic growth, rises in income
levels, and residence in urban areas [28, 29]; geographic
factors such as exposure to northern climates [9]; and lifestyle

factors such as tobacco smoking, use of oral contraceptives,
diet, and psychological stress [9, 28].
CD has a reported incidence 3.1 to 14.6 cases per 100,000
person-years in North America and exhibits a bimodal age
distribution, the first peak occurring in early adulthood and
the second peak at 50 to 70 years of age [4]. The most
common sites of involvement at initial diagnosis are the
terminal ileum, ileocecal valve, and cecum [9]. However, any
region of the GI tract may be affected, including other areas
of the small and large intestines as well as the upper GI tract
and oral cavity [4]. The clinical symptoms of CD can vary
from patient to patient and depend primarily on the location
and behavior of the lesions, disease severity and activity, and
the involvement of extraintestinal sites. The most common
symptoms include periumbilical or lower right quadrant
pain, nonbloody diarrhea of greater than six months in
duration, and weight loss accompanied by low-grade fever,
malaise, and fatigue [4, 9]. This constellation of findings is
believed to represent a harbinger for disease, especially in
children [4]. In addition to the aforementioned symptoms,
pediatric patients may experience fever of unknown origin,
arthralgia, decreased growth, and failure to thrive [9, 30].
Laboratory findings are often nonspecific but may show
evidence of GI malabsorption (e.g., low albumin, calcium,
folate, iron, and red blood cell count), elevated erythrocyte
sedimentation rate (ESR), elevated platelet counts, anemia,
and increased acute phase reactants such as C-reactive
protein [31–34]. Typical of most immune-mediated disorders,
CD follows a chronic, indolent course characterized by
periods of relapse and remission. However, the chronic nature
of the inflammation ultimately predisposes patients to local
complications such as strictures, fistulas, intra-abdominal
abscesses, and bowel obstruction [9, 31]. These complications
often compromise long-term intestinal function and may
require surgical correction with time [4]. Recurrence of CD
following surgery is common and is promoted by a number of
factors such as a history of penetrating disease, young patient
age, ileocolonic disease, and cigarette smoking [35, 36].
Lastly, CD patients are at risk for developing dysplasia or
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Table 1: Oral manifestations of Crohn’s disease.
Site(s)

Characteristics

Lips, buccal mucosa

Labial enlargement, firm to palpation, typically painless

Buccal mucosa, vestibule

Mucosal edema with or without fissuring

Attached gingiva, alveolar mucosa
Vestibule, buccal mucosa, tongue, palate
Buccal mucosa, vestibule

Patchy erythematous macules or plaques with or without hyperplasia
Deep ulcerations with or without hyperplastic margins
Hyperplasia of mucosa, firm or boggy to palpation

adenocarcinoma of the small intestine or colorectal mucosa
[37]. Periodic colonoscopic surveillance is therefore a crucial
aspect of management [9, 38, 39].
CD is characterized by an array of findings on endoscopic
and microscopic examination. In contrast to ulcerative colitis,
the pathologic lesions of CD occur in a segmented and
discontinuous distribution [4, 9]. Identification of such “skip”
lesions—sharply demarcated areas of disease surrounded by
completely normal mucosa [9]—is considered a cornerstone
in the diagnosis of CD. Once diagnosed, the patient must then
undergo further evaluation such as imaging studies to assess
the location and extent of lesions as well as the presence of
complications [40–42].
It has been estimated that approximately 47% of patients
with IBD exhibit extraintestinal manifestations (EIMs) which
most frequently involve the skin, eyes, joints, liver, biliary
tract, and lungs [4, 9]. Interestingly, the presence of one EIM
has been shown to predispose to development of additional
EIMs [4]. Involvement of the oral mucosa, termed oral CD,
has a widely disparate prevalence rate of 0.5 to 80.0% [4,
6, 7, 43–47] that is likely attributable to differences in study
inclusion criteria [4, 48]. It may precede, occur concurrently,
or follow the onset of abdominal symptoms [31]. Synchronous or metachronous observation of oral lesions is most
commonly described, although Plauth et al. [45] reported
oral CD as the presenting symptom in 60% of their patients.
Oral lesions considered pathognomonic for CD include
persistent lip swelling, cobblestoning of the oral mucosa,
mucogingivitis, deep linear or serpiginous ulcerations surrounded by epithelial hyperplasia, and tissue tags or polyps
(Table 1) [4, 5, 31, 49, 50]. These may be associated with pain,
impairment of oral function, and psychosocial stress [45].
It is important to bear in mind that affected patients may
not always present with these classic lesions and detection
of oral CD can be challenging, particularly if the lesions
are subtle or the patient is in early stages of disease. Other
oral findings that may be seen include aphthous ulcerations,
angular cheilitis, stomatitis, glossitis, and perioral dermatitis
[4]. However, these are considered nonspecific for CD as they
may represent primary manifestations of disease or occur
secondary to nutritional deficiencies induced by intestinal
malabsorption, dietary restriction, or medications [4, 50].
Oral CD often demonstrates a young age of presentation
and is most frequently seen in adolescents and young adults
[45]. Interestingly, Hussey et al. [51] reported that only 29%

of the children in their study continued to harbor CDspecific oral lesions over a mean follow-up of 55 months
and emphasized the need for timely recognition and biopsy
in the pediatric population. Harty et al. [47] reported the
presence of granulomatous inflammation in 100% of the
biopsies performed in their study and reiterated the value
of the easily accessible oral mucosa as a potential site for
harvesting diagnostic material, especially in children.
The clinical differential diagnosis for oral CD in a pediatric patient is broad and encompasses a variety of conditions
that may present with oral mucosal swellings, masses, and/or
ulcerations as follows:

Lesion
Persistent mucosal
swelling
Cobblestoning of
mucosa
Mucogingivitis
Linear ulcerations
Mucosal tags or polyps
Adapted from Kalmar [31].

Multifocal Mucosal Swelling and Cobblestoning of Mucosa
Idiopathic orofacial granulomatosis
Neurofibromatosis
Multiple endocrine neoplasia (MEN) 2B/III
Multiple hamartoma syndrome (Cowden disease)
Multifocal epithelial hyperplasia (Heck’s disease)
Amyloidosis.
Ulcerations (Linear and Aphthous-Like)
Recurrent aphthous stomatitis
Aphthous ulcerations associated with an underlying
systemic disease including
celiac disease,
ulcerative colitis,
immunocompromised conditions (e.g., HIV
and AIDS),
hematologic disorders (e.g., neutropenia, cyclic
neutropenia, and leukemia),
nutritional deficiencies,
MAGIC syndrome (i.e., mouth and genital
ulcers with inflamed cartilage),
PFAPA syndrome (i.e., periodic fever, aphthous
stomatitis, pharyngitis, and cervical adenitis),
Behçet’s syndrome.
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Viral infections including
herpes simplex infection,
varicella zoster infection,
enterovirus infection (e.g., hand-foot-mouth
disease and herpangina).
Traumatic ulcerations
Chemical or thermal burns
Pemphigus vulgaris
Mucous membrane pemphigoid
Erythema multiforme.
Swellings and/or Ulcerations That Exhibit Granulomatous
Inflammation on Microscopic Examination
Foreign body reaction and foreign body gingivitis
Allergy
Orofacial granulomatosis, including MelkerssonRosenthal syndrome and cheilitis granulomatosa
Sarcoidosis
Tuberculosis
Leprosy
Deep fungal infections (e.g., histoplasmosis, blastomycosis, paracoccidioidomycosis, and coccidioidomycosis)
Tertiary syphilis.
Diagnostic considerations prior to histologic examination
include idiopathic orofacial granulomatosis; syndromes presenting with multiple mucosal swellings, such as neurofibromatosis, multiple endocrine neoplasia (MEN) 2B/III, and
multiple hamartoma syndrome (Cowden disease); aphthous
ulcerations in the presence or absence of an underlying
systemic disease; and other vesiculoerosive diseases of various etiologies. The differential diagnosis for histologically
confirmed oral granulomatous inflammation in a younger
patient can be broadly subcategorized into disorders of localized or systemic etiology. Localized causes of granulomatous
inflammation include a foreign body reaction (e.g., granulomatous gingivitis); allergic reaction to cinnamon or benzoate; and idiopathic orofacial granulomatosis, a diagnosis of exclusion that requires elimination of other defined
causes of granulomatous inflammation. Systemic conditions
associated with granulomatous inflammation include Crohn’s
disease, sarcoidosis, mycobacterial infections, deep fungal
infections, and tertiary syphilis. Ultimately, the diagnosis of
CD hinges on careful correlation between the patient’s clinical
history and findings on physical, radiographic, endoscopic,
laboratory, and microscopic examinations.
The management of CD is dependent on the disease
location and activity as well as the presence of complications
[4]. The predominant classes of medications used in the
treatment of CD include anti-inflammatory agents such as
aminosalicylates and steroids, immunosuppressants or
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immunomodulators such as thiopurines and methotrexate,
and biologic agents such as infliximab. The standard “stepup” protocol advocates use of oral corticosteroid therapy for
patients with mild-to-moderate CD localized to the ileocecal
region [52] and a combination of oral corticosteroids and
immunosuppressants for patients with moderate-to-severe
small bowel disease and relapsing or steroid-refractory
disease [52–54]. Biologic agents are recommended for
patients who do not respond to or cannot tolerate standard
therapy and in whom corticosteroids are contraindicated [4].
Surgery is typically postponed for as long as possible as it is
not considered curative and may be associated with a number of functional complications and recurrence of disease
[4]. Recently, there has been a shift in favor of administering
biologic agents such as infliximab in patients with newly
diagnosed CD, a so-called “top-down” approach [55]. It is
believed that introduction of biologics early in disease may
disrupt the natural evolution of CD from the inflammatory
stage to the advanced stages, which is generally less responsive to pharmacologic therapy and more often associated
with the development of complications [4, 56]. Management
is more complex in the pediatric population because of the
potential impact of CD medications on growth and development. The overall goals of CD treatment in children are to
achieve the best possible control of disease with the least
adverse effects, to promote continued growth through nutrition, and to enable the child to maintain normal day-to-day
activities such as attending school [57]. Although no standardized protocol exists, most clinicians follow a step-up
approach of administering an aminosalicylate, antibiotics,
and nutritional therapy, followed by the addition of corticosteroid, immunomodulatory, and biologic therapy as
deemed necessary [57]. As with adult CD, there is early
evidence to support the top-down approach but further studies are necessary before widespread implementation [57].
Exclusive enteral nutrition (EN), also known as tube feeding,
is another therapeutic option in children with CD [58, 59].
Pain associated with oral CD can be managed with topical,
systemic, or injectable steroids with or without the use of
immunosuppressive agents such as azathioprine [31, 45];
however, oral lesions typically respond well to systemic
treatment of intestinal CD [50].
In summary, we have described a 6-year-old male with
oral lesions as his initial manifestation of CD. This case underscores the importance of recognizing the variable, sometimes
subtle, presentation of oral CD and performing necessary
diagnostic procedures, such as biopsy for histopathologic
confirmation. Astute identification of oral lesions is key as
studies have shown that only a minority of patients will
continue to exhibit oral findings at follow-up [51]. In addition,
it has been reported that the ability of physicians to identify
oral CD was poor when a dentist’s exam was used as a
comparator [47]. The dental practitioner is therefore in a
unique position to detect oral CD, which may be the only
manifestation of occult disease in patients who are otherwise
asymptomatic. This may lead to early diagnosis, timely treatment, and ultimately a better outcome in affected patients.
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